Supernus Pharm (SUPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Sales | 520,397 | 392,755 | 408,897 | 302,238 | 215,003 |
| Cost of Goods | 52,459 | 16,660 | 15,356 | 15,215 | 11,986 |
| Gross Profit | 467,938 | 376,095 | 393,541 | 287,023 | 203,017 |
| Operating Expenses | 294,699 | 228,184 | 249,453 | 187,697 | 149,787 |
| Operating Income | 173,698 | 148,571 | 144,444 | 99,541 | 54,216 |
| Interest Expense | 23,754 | 22,707 | 18,111 | 1,568 | 5,091 |
| Other Income | 18,704 | 21,623 | 13,843 | 2,645 | 1,244 |
| Pre-tax Income | 168,648 | 147,487 | 140,176 | 100,618 | 50,369 |
| Income Tax | 41,698 | 34,431 | 29,183 | 43,334 | -40,852 |
| Net Income Continuous | 126,950 | 113,056 | 110,993 | 57,284 | 91,221 |
| Net Income | $126,950 | $113,056 | $110,993 | $57,284 | $91,221 |
| EPS Basic Total Ops | 2.41 | 2.16 | 2.13 | 1.13 | 1.84 |
| EPS Basic Continuous Ops | 2.41 | 2.16 | 2.13 | 1.13 | 1.84 |
| EPS Diluted Total Ops | 2.36 | 2.10 | 2.05 | 1.08 | 1.76 |
| EPS Diluted Continuous Ops | 2.36 | 2.10 | 2.05 | 1.07 | 1.76 |
| EPS Diluted Before Non-Recurring Items | 2.36 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $205,531 | $166,904 | $161,690 | $107,160 | $57,135 |